The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community.
View all episodes
By BiotechTV
5
44 ratings
The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community.
30,626 Listeners
1,863 Listeners
1,085 Listeners
325 Listeners
6,059 Listeners
60 Listeners
9,840 Listeners
86 Listeners
34 Listeners
19 Listeners
260 Listeners
497 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners